This was accompanied by increased phosphorylation of GSK3β in the liver, an indication of the activation of insulin signalling.142 These findings supported the idea that inhibition of SHIP2 has therapeutic potential as a treatment for T2D. Here, INPPL1 is linked to type 2 diabetes mellitus.